Strides Pharma Science Limited (BOM:532531)

India flag India · Delayed Price · Currency is INR
887.45
+17.35 (1.99%)
At close: Jul 11, 2025
-5.35%
Market Cap 81.82B
Revenue (ttm) 45.65B
Net Income (ttm) 35.93B
Shares Out n/a
EPS (ttm) 390.50
PE Ratio 2.28
Forward PE 17.09
Dividend 2.50 (0.29%)
Ex-Dividend Date Sep 9, 2024
Volume 11,263
Average Volume 22,678
Open 870.10
Previous Close 870.10
Day's Range 870.10 - 893.00
52-Week Range 530.70 - 1,675.25
Beta n/a
RSI 61.49
Earnings Date Jul 31, 2025

About Strides Pharma Science

Strides Pharma Science Limited develops, manufactures, and sells pharmaceutical products in Africa, Australia, North America, Europe, Asia, India, and internationally. It operates through two segments, Pharmaceutical and Biopharmaceutical. The company offers pharma generics in various forms, such as tablets, hard and soft gelatin capsules, sachets, and liquids, as well as nasal spray, gels, powders, solids, ointments, and creams. It also develops branded generics products for the treatment of chronic therapies, including women’s health, central... [Read more]

Industry Pharmaceutical Preparations
Founded 1990
Employees 3,065
Stock Exchange Bombay Stock Exchange
Ticker Symbol 532531
Full Company Profile

Financial Performance

Financial Statements

News

Strides Pharma receives USFDA approval for Celecoxib Capsules

Strides Pharma Science Limited announced that its stepdown wholly owned subsidiary, Strides Pharma Global Pte. Limited, based in Singapore, has received approval from the United States Food & Drug Adm...

2 months ago - Business Upturn

Strides Pharma incorporates new subsidiary ‘Pivot Path’ to boost life sciences and digital innovation

Strides Pharma Science Limited has announced the incorporation of a new step-down wholly owned subsidiary named Pivot Path Private Limited through its subsidiary Arco Lab Private Limited. The new enti...

3 months ago - Business Upturn

Strides Pharma shares surge 5% as revenue jumps 15% YoY in Q3 FY25

Strides Pharma Science Limited’s shares rose 5% following the release of its Q3 FY25 financial results, showcasing robust year-on-year (YoY) growth and a strong profit recovery. As of 1:43 PM, the sha...

5 months ago - Business Upturn

Strides Pharma Q3 FY25 Results: Revenue up 15% YoY to Rs 1,154 crore, Net Profit up 60% YoY

Strides Pharma Science Limited reported its Q3 FY25 financial performance with strong year-on-year (YoY) revenue growth and a significant improvement in net profit. The company’s revenue from operatio...

5 months ago - Business Upturn

Strides Pharma receives USFDA approval for acetaminophen and ibuprofen tablets, expanding OTC portfolio

Strides Pharma Science Limited has announced a significant milestone with USFDA approval for acetaminophen and ibuprofen tablets, 125 mg/250 mg. This development is set to enhance the company’s over-t...

6 months ago - Business Upturn